Glenmark Pharmaceuticals Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Glenmark Pharmaceuticals şirketinin kazançları yıllık ortalama -51.2% oranında azalırken, Pharmaceuticals sektörünün kazançları yıllık 13.3% oranında artan oldu. Gelirler yıllık ortalama 5.3% oranında artan oldu.
Anahtar bilgiler
-51.2%
Kazanç büyüme oranı
-51.2%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 17.5% |
| Gelir büyüme oranı | 5.3% |
| Özkaynak getirisi | -11.8% |
| Net Marj | -7.8% |
| Son Kazanç Güncellemesi | 30 Sep 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Pinning Down Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) P/S Is Difficult Right Now
Oct 26
This Is Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Looks Appropriate
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Is Paying Out A Dividend Of ₹2.50
Sep 06Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 06Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?
Jun 16Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value
May 08Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?
Dec 07Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 23Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50
Sep 17Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 30A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 28We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt
Jul 03A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
May 28Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet
Mar 22Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Feb 14An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued
Oct 12Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 29We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Jun 20There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings
Jun 04An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued
May 05If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late
Mar 25Gelir ve Gider Dağılımı
Gelir ve Gider Dağılımı
Glenmark Pharmaceuticals nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Sep 24 | 130,799 | -10,183 | 35,523 | 0 |
| 30 Jun 24 | 128,612 | -15,732 | 28,973 | 0 |
| 31 Mar 24 | 126,454 | -18,990 | 34,694 | 0 |
| 31 Dec 23 | 131,575 | -7,640 | 35,454 | 0 |
| 30 Sep 23 | 137,510 | -1,263 | 34,998 | 0 |
| 30 Jun 23 | 136,144 | 2,546 | 28,740 | 0 |
| 31 Mar 23 | 116,556 | -1,697 | 31,833 | 0 |
| 31 Dec 22 | 126,355 | 8,811 | 31,713 | 0 |
| 30 Sep 22 | 123,451 | 8,305 | 30,013 | 0 |
| 30 Jun 22 | 121,173 | 8,277 | 24,874 | 0 |
| 31 Mar 22 | 123,049 | 9,417 | 29,176 | 0 |
| 31 Dec 21 | 122,103 | 10,202 | 28,735 | 0 |
| 30 Sep 21 | 118,248 | 10,464 | 28,841 | 0 |
| 30 Jun 21 | 116,144 | 10,226 | 24,305 | 0 |
| 31 Mar 21 | 109,439 | 9,700 | 28,103 | 0 |
| 31 Dec 20 | 107,778 | 9,565 | 29,386 | 0 |
| 30 Sep 20 | 107,445 | 8,992 | 28,992 | 0 |
| 30 Jun 20 | 106,629 | 9,207 | 22,777 | 0 |
| 31 Mar 20 | 106,573 | 7,760 | 28,627 | 0 |
| 31 Dec 19 | 104,370 | 7,173 | 29,403 | 0 |
| 30 Sep 19 | 102,564 | 6,428 | 28,861 | 0 |
| 30 Jun 19 | 100,227 | 7,680 | 20,903 | 0 |
| 31 Mar 19 | 98,655 | 9,250 | 28,738 | 0 |
| 31 Dec 18 | 95,532 | 8,863 | 26,688 | 0 |
| 30 Sep 18 | 92,018 | 8,721 | 26,317 | 0 |
| 30 Jun 18 | 89,057 | 6,716 | 19,400 | 0 |
| 31 Mar 18 | 90,744 | 8,039 | 25,149 | 0 |
| 31 Dec 17 | 91,908 | 6,420 | 25,123 | 0 |
| 30 Sep 17 | 95,055 | 10,083 | 24,474 | 0 |
| 30 Jun 17 | 94,896 | 10,233 | 23,733 | 0 |
| 31 Mar 17 | 90,794 | 9,160 | 23,601 | 0 |
| 31 Dec 16 | 89,316 | 10,402 | 21,486 | 0 |
| 30 Sep 16 | 81,749 | 7,508 | 20,918 | 0 |
| 30 Jun 16 | 78,414 | 7,292 | 20,078 | 0 |
| 31 Mar 16 | 75,732 | 7,021 | 19,219 | 0 |
| 31 Dec 15 | 70,300 | 5,697 | 25,618 | 1,624 |
| 30 Sep 15 | 69,530 | 5,141 | 25,335 | 1,624 |
| 30 Jun 15 | 67,244 | 4,814 | 24,904 | 1,624 |
| 31 Mar 15 | 65,561 | 4,753 | 15,454 | 0 |
| 31 Dec 14 | 64,891 | 5,078 | 21,404 | 1,414 |
| 30 Sep 14 | 63,983 | 6,092 | 20,973 | 1,414 |
| 30 Jun 14 | 61,897 | 5,984 | 20,065 | 1,414 |
| 31 Mar 14 | 59,450 | 5,423 | 19,409 | 1,414 |
| 31 Dec 13 | 56,441 | 6,660 | 9,575 | 0 |
Kaliteli Kazançlar: GLENMARK şu anda kârlı değil.
Büyüyen Kar Marjı: GLENMARK şu anda kârlı değil.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: GLENMARK kârlı değildir ve zararlar son 5 yılda yılda 51.2% oranında artmıştır.
Büyüme Hızlandırma: GLENMARK 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil
Kazançlar vs. Sektör: GLENMARK kârlı olmadığından, geçmiş yıl kazanç büyümesinin Pharmaceuticals sektörüyle ( 20.5% ) karşılaştırılması zorlaşıyor.
Özkaynak Getirisi
Yüksek ROE: GLENMARK hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -11.76% ) sahiptir.